Information
-
Trademark
-
79275839
-
Serial Number
79275839
-
Registration Number
6279502
-
International Classifications
-
Filing Date
July 25, 2019
5 years ago
-
Registration Date
March 02, 2021
3 years ago
-
Transaction Date
January 19, 2024
a year ago
-
Status Date
March 02, 2021
3 years ago
-
Published for Opposition Date
December 15, 2020
4 years ago
-
Location Date
March 02, 2021
3 years ago
-
Status Code
700
-
Current Location
PUBLICATION AND ISSUE SECTION
Employee Name
AGREDA, SAMANTHA LEIGH
-
Attorney Docket Number
US-SHUS-026A
Attorney Name
Stacey J. Watson
Law Office Assigned Location Code
N50
-
Owners
Mark Drawing Code
3000
Mark Identification
I
Case File Statements
- DM0000: The mark consists of six shapes; The top two shapes colored in lime green resemble a lowercase letter "I"; Each of the remaining four shapes colored in forest green are comprised of one or more right ascending diagonal strokes with rounded edges of varying length; Two of the shapes colored in forest green are comprised of multiple right ascending diagonal strokes, what are connected by left ascending diagonal strokes of varying width with concave sides.
- GS0051: Pharmaceutical preparations for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, and biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical biological preparations for medical purposes for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical preparations for human use, namely, analgesics, antibiotics, anti-fungals, anti-infective preparations, anti-virals, anti-parasitics, and cytokine inhibitory drugs; human growth hormones, immunosuppressants, immunotherapies for the treatment of cancer, medicated dermatological preparations, pharmaceutical antibodies for disease testing, diagnosis, and treatment purposes, pharmaceutical preparations that modulate the immune system, pharmaceutical and biological preparations for immunotherapy, including T Cell therapy, sedatives, smoking cessation preparations, tranquillizers, vaccines for human use, and vitamins; and preparations for destroying vermin, fungicides, herbicides
- PM0001: !
- CC0000: The colors lime green and forest green are claimed as a feature of the mark.
- GS0441: Medical screening; providing information relating to medical services; genetic testing for medical purposes
- GS0421: Structural and functional analysis of genomes; research and development in the field of microorganisms and cells for the healthcare, scientific, biochemical, pharmaceutical, medical, agricultural, food, cosmetic, animal health, diagnostic, chemical, bioremediation, sanitation, oral care, and oil industries; pharmaceutical research and development; pharmaceutical product evaluation services; medical research; medical laboratory services; genetic testing for scientific research purposes
Case File Event Statements
-
1/19/2024 - a year ago
35 - NEW REPRESENTATIVE AT IB RECEIVED
Type: NREP
-
6/20/2021 - 3 years ago
34 - FINAL DECISION TRANSACTION PROCESSED BY IB
Type: FINO
-
6/2/2021 - 3 years ago
33 - FINAL DISPOSITION NOTICE SENT TO IB
Type: FICS
-
6/2/2021 - 3 years ago
32 - FINAL DISPOSITION PROCESSED
Type: FIMP
-
6/2/2021 - 3 years ago
31 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Type: FICR
-
3/2/2021 - 3 years ago
30 - REGISTERED-PRINCIPAL REGISTER
Type: R.PR
-
12/15/2020 - 4 years ago
29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
12/15/2020 - 4 years ago
28 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
11/25/2020 - 4 years ago
27 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
11/12/2020 - 4 years ago
26 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
11/12/2020 - 4 years ago
25 - EXAMINER'S AMENDMENT ENTERED
Type: XAEC
-
11/12/2020 - 4 years ago
24 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Type: GNEN
-
11/12/2020 - 4 years ago
23 - EXAMINERS AMENDMENT E-MAILED
Type: GNEA
-
11/12/2020 - 4 years ago
22 - EXAMINERS AMENDMENT -WRITTEN
Type: CNEA
-
8/31/2020 - 4 years ago
21 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
8/31/2020 - 4 years ago
20 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
8/31/2020 - 4 years ago
19 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
8/5/2020 - 4 years ago
18 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
8/4/2020 - 4 years ago
17 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
8/4/2020 - 4 years ago
16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
7/10/2020 - 4 years ago
15 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Type: CHAN
-
7/10/2020 - 4 years ago
14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED
Type: TCCA
-
7/10/2020 - 4 years ago
13 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Type: ECDR
-
7/10/2020 - 4 years ago
12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Type: ARAA
-
7/10/2020 - 4 years ago
11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Type: REAP
-
7/10/2020 - 4 years ago
10 - TEAS CHANGE OF OWNER ADDRESS RECEIVED
Type: COAR
-
2/28/2020 - 4 years ago
9 - REFUSAL PROCESSED BY IB
Type: RFNT
-
2/10/2020 - 4 years ago
8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Type: RFCS
-
2/10/2020 - 4 years ago
7 - REFUSAL PROCESSED BY MPU
Type: RFRR
-
1/17/2020 - 5 years ago
6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Type: RFCR
-
1/16/2020 - 5 years ago
5 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
1/14/2020 - 5 years ago
4 - APPLICATION FILING RECEIPT MAILED
Type: MAFR
-
1/9/2020 - 5 years ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
1/9/2020 - 5 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
1/2/2020 - 5 years ago
1 - SN ASSIGNED FOR SECT 66A APPL FROM IB
Type: REPR